BRPI0417844A - derivados de amida contendo um substituinte de ciclopropilaminocarbonila, de utilidade como inibidores de citocina - Google Patents

derivados de amida contendo um substituinte de ciclopropilaminocarbonila, de utilidade como inibidores de citocina

Info

Publication number
BRPI0417844A
BRPI0417844A BRPI0417844-0A BRPI0417844A BRPI0417844A BR PI0417844 A BRPI0417844 A BR PI0417844A BR PI0417844 A BRPI0417844 A BR PI0417844A BR PI0417844 A BRPI0417844 A BR PI0417844A
Authority
BR
Brazil
Prior art keywords
amide derivatives
derivatives containing
cyclopropylaminocarbonyl
cytokine inhibitors
cytokine
Prior art date
Application number
BRPI0417844-0A
Other languages
English (en)
Inventor
John Graham Cumming
Ian Alun Nash
Dearg Sutherland Brown
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30776197&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0417844(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0417844A publication Critical patent/BRPI0417844A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/06—1,2,3-Thiadiazoles; Hydrogenated 1,2,3-thiadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"DERIVADOS DE AMIDA CONTENDO UM SUBSTITUINTE DE CICLOPROPILAMINOCARBONILA, DE UTILIDADE COMO INIBIDORES DE CITOCINA". A presente invenção refere-se a um composto de fórmula (I), em que Q~ a~ representa heteroarila que é substituído por halogênio; R~ 1~ e R~ 2~ representam cada qual hidrogênio; e Q~ b~ representa fenila ou heteroarila, Q~ b~ podendo opcionalmente conter 1 ou 2 substituintes, selecionados de hidróxi, halogênio e (C~ 1-6~)alquila ou um sal farmaceuticamente aceitável do mesmo; a processos para sua preparação, a composições farmacêuticas contendo os mesmos e seu uso no tratamento de doenças ou condicionamentos médicos mediados por citocinas.
BRPI0417844-0A 2003-12-20 2004-12-15 derivados de amida contendo um substituinte de ciclopropilaminocarbonila, de utilidade como inibidores de citocina BRPI0417844A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0329572.2A GB0329572D0 (en) 2003-12-20 2003-12-20 Amide derivatives
PCT/GB2004/005241 WO2005061465A1 (en) 2003-12-20 2004-12-15 Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cyto kine inhibitors

Publications (1)

Publication Number Publication Date
BRPI0417844A true BRPI0417844A (pt) 2007-04-17

Family

ID=30776197

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417844-0A BRPI0417844A (pt) 2003-12-20 2004-12-15 derivados de amida contendo um substituinte de ciclopropilaminocarbonila, de utilidade como inibidores de citocina

Country Status (34)

Country Link
US (3) US7943776B2 (pt)
EP (1) EP1699766B1 (pt)
JP (1) JP5046650B2 (pt)
KR (1) KR101151530B1 (pt)
CN (1) CN1918134B (pt)
AR (1) AR046968A1 (pt)
AT (1) ATE477246T1 (pt)
AU (1) AU2004303579B8 (pt)
BR (1) BRPI0417844A (pt)
CA (1) CA2547617C (pt)
CY (1) CY1111980T1 (pt)
DE (1) DE602004028656D1 (pt)
DK (1) DK1699766T3 (pt)
ES (1) ES2350226T3 (pt)
GB (1) GB0329572D0 (pt)
HK (1) HK1092797A1 (pt)
HR (1) HRP20100592T1 (pt)
IL (1) IL175998A0 (pt)
ME (1) ME01851B (pt)
MX (1) MXPA06006660A (pt)
MY (1) MY145908A (pt)
NO (1) NO337886B1 (pt)
NZ (1) NZ547998A (pt)
PL (1) PL1699766T3 (pt)
PT (1) PT1699766E (pt)
RS (1) RS51417B (pt)
RU (1) RU2382028C2 (pt)
SA (1) SA04250419B1 (pt)
SI (1) SI1699766T1 (pt)
TW (1) TWI342214B (pt)
UA (1) UA88777C2 (pt)
UY (1) UY28688A1 (pt)
WO (1) WO2005061465A1 (pt)
ZA (1) ZA200604973B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308201D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
GB0308186D0 (en) 2003-04-09 2003-05-14 Smithkline Beecham Corp Novel compounds
RU2342365C2 (ru) 2003-05-01 2008-12-27 Бристол-Маерс Сквибб Компани Арилзамещенные пиразоламиды в качестве ингибиторов киназ
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
US7754717B2 (en) 2005-08-15 2010-07-13 Amgen Inc. Bis-aryl amide compounds and methods of use
EP2468717B1 (en) * 2006-10-27 2013-11-20 Bristol-Myers Squibb Company Heterocyclic Amide Compounds Useful as Kinase Inhibitors
US20090281150A1 (en) * 2008-04-09 2009-11-12 Nicola Frances Bateman Compound 249
WO2009138778A1 (en) * 2008-05-12 2009-11-19 Astrazeneca Ab Cyclopropyl benzamide derivatives as intermediates for cytokine inhibitors
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
WO2011010132A1 (en) 2009-07-21 2011-01-27 Astrazeneca Ab Sustained-release composition comprising compound 600
WO2016001452A1 (en) * 2014-07-04 2016-01-07 Universität Zürich Compounds, in particular for use in the treatment of a disease or condition for which a bromodomain inhibitor is indicated
EP3585768A4 (en) * 2017-02-24 2020-12-23 Taiwanj Pharmaceuticals Co., Ltd. SULFONAMIDE OR AMIDE COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE PROPHYLAXIS AND / OR TREATMENT OF AUTOIMMUNE, INFLAMMATORY, OR INFECTIOUS DISEASES
WO2024039864A1 (en) * 2022-08-19 2024-02-22 Purdue Research Foundation Protein:protein interaction inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816837D0 (en) * 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US7772432B2 (en) * 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
WO1999046248A1 (en) * 1998-03-09 1999-09-16 Vertex Pharmaceuticals Incorporated 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors
GB2336362A (en) * 1998-04-17 1999-10-20 Xenova Ltd Cytokine production inhibitors
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
US7169771B2 (en) * 2003-02-06 2007-01-30 Bristol-Myers Squibb Company Thiazolyl-based compounds useful as kinase inhibitors
US7263483B2 (en) * 2003-04-28 2007-08-28 Dictaphone Corporation USB dictation device
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives

Also Published As

Publication number Publication date
IL175998A0 (en) 2006-10-05
CN1918134B (zh) 2010-11-10
TW200524620A (en) 2005-08-01
MXPA06006660A (es) 2006-08-11
PT1699766E (pt) 2010-10-11
PL1699766T3 (pl) 2011-01-31
AU2004303579A1 (en) 2005-07-07
RU2006125634A (ru) 2008-01-27
CA2547617A1 (en) 2005-07-07
ME01851B (me) 2011-02-28
GB0329572D0 (en) 2004-01-28
SI1699766T1 (sl) 2010-12-31
US7943776B2 (en) 2011-05-17
SA04250419B1 (ar) 2009-01-19
DE602004028656D1 (en) 2010-09-23
CA2547617C (en) 2013-02-05
US20070135440A1 (en) 2007-06-14
US20120004243A1 (en) 2012-01-05
RU2382028C2 (ru) 2010-02-20
JP5046650B2 (ja) 2012-10-10
UY28688A1 (es) 2005-07-29
RS51417B (en) 2011-02-28
CY1111980T1 (el) 2015-11-04
US20130035346A1 (en) 2013-02-07
US8742124B2 (en) 2014-06-03
HK1092797A1 (en) 2007-02-16
NO337886B1 (no) 2016-07-04
UA88777C2 (en) 2009-11-25
TWI342214B (en) 2011-05-21
KR101151530B1 (ko) 2012-07-05
DK1699766T3 (da) 2010-11-01
KR20060123352A (ko) 2006-12-01
NO20063330L (no) 2006-09-14
ES2350226T3 (es) 2011-01-20
AU2004303579B2 (en) 2008-04-03
ZA200604973B (en) 2007-05-30
EP1699766A1 (en) 2006-09-13
NZ547998A (en) 2009-03-31
ATE477246T1 (de) 2010-08-15
WO2005061465A1 (en) 2005-07-07
AR046968A1 (es) 2006-01-04
EP1699766B1 (en) 2010-08-11
JP2007516979A (ja) 2007-06-28
CN1918134A (zh) 2007-02-21
HRP20100592T1 (hr) 2010-12-31
MY145908A (en) 2012-05-15
AU2004303579B8 (en) 2008-05-01

Similar Documents

Publication Publication Date Title
BRPI0415746A (pt) derivados de amida
RU2495044C2 (ru) Ингибиторы активности протеинтирозинкиназы
RU2397168C2 (ru) Производные тиофена в качестве ингибиторов снк 1
BRPI0519287A2 (pt) derivados de amida
HUP0402310A2 (hu) 1,6-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
BRPI0511504A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, e, agente preventivo ou terapêutico para uma doença resultante de beta-amilóides
BRPI0417844A (pt) derivados de amida contendo um substituinte de ciclopropilaminocarbonila, de utilidade como inibidores de citocina
SE0104334D0 (sv) Therapeutic agents
BR0010520A (pt) Novos compostos farmaceuticamente ativos
BRPI0409110A (pt) derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer
BRPI0409641A (pt) 1-4-diazepinas substituìdas e seu uso
MXPA03011638A (es) Nuevos derivados de 4-piperazinil indol con afinidad por el receptor 5-ht6.
BR0307409A (pt) Compostos de hidrazida de ácido 2-furanocarboxìlico, composições farmacêuticas contendo os mesmos e uso dos mesmos para preparação de um agente preventivo ou terapêutico
ATE437872T1 (de) Proteinkinaseinhibitoren
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
BRPI0414514A (pt) uso de um composto, composto, e, composições farmacêuticas
BRPI0515628A (pt) composto de 2-morfolina-4-pirimidona
BR0015193A (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de uma condição associada com trasmissão reduzida de nicotina, para tratamento ou profilaxia de distúrbios psicóticos ou distúrbios de deterioração intelectual e para tratamento ou profilaxia de doenças ou condições humanas
ATE307810T1 (de) Imidazol-2-carbonsäureamid derivate als raf- kinase-inhibitoren
BRPI0508047A (pt) derivados de alquilpiperazina-e alquil-homopiperazina-carboxilatos, o respectivo preparo e a respectiva aplicação como inibidores da enzima faah
BRPI0408591A (pt) derivados de 6,7,8,9-tetrahidropirimido[1,2-a] pirimidin-4-ona 8-substituìda
BRPI0517259A (pt) novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
EA200300424A1 (ru) Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов
BR0316950A (pt) Derivados de indazol como antagonistas de crf
ES2149777T3 (es) Derivados de triazol que tienen actividad antifungica.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements